Yahoo
ASX - Delayed Quote AUD

LTR Pharma Limited (LTP.AX)

0.4300 0.0000 (0.00%)
At close: 3:57:11 PM GMT+11
Chart Range Bar
Loading chart for LTP.AX
  • Previous Close 0.4300
  • Open 0.4200
  • Bid 0.4150 x --
  • Ask 0.4200 x --
  • Day's Range 0.4050 - 0.4400
  • 52 Week Range 0.3500 - 0.7500
  • Volume 170,081
  • Avg. Volume 145,740
  • Market Cap (intraday) 78.378M
  • Beta (5Y Monthly) 2.20
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0800
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.

ltrpharma.com

--

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

LTP.AX
40.28%
S&P/ASX 200 [XJO] (^AXJO)
1.63%

1-Year Return

LTP.AX
9.47%
S&P/ASX 200 [XJO] (^AXJO)
0.43%

3-Year Return

LTP.AX
22.86%
S&P/ASX 200 [XJO] (^AXJO)
26.92%

5-Year Return

LTP.AX
22.86%
S&P/ASX 200 [XJO] (^AXJO)
19.80%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -32.96%

  • Return on Equity (ttm)

    -54.73%

  • Revenue (ttm)

    723.93k

  • Net Income Avi to Common (ttm)

    -14.16M

  • Diluted EPS (ttm)

    -0.0800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.66M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -6.51M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: